DiaGenic has been granted NOK 7.8 million of the Norwegian Research
Council`s BIA funds. The funds will be employed in an industry-oriented
research project to improve robustness and reduce costs of procedure in
blood based diagnostics of Alzheimer's disease. The clinical samples
will be sourced from DiaGenic's biobank as well as the HUNT Biosciences
biobank.
The grant announcement for the project "Blood microRNAs for the early
diagnosis of Alzheimer's disease" was made public today by the Research
Council of Norway and is conditional upon signature by the parties.

"Norwegian Research Council has in the past contributed with significant
funding for DiaGenic's development of diagnostic tests. This new grant
for development of blood based diagnostics for early Alzheimer's disease
represents an important financial contribution", says CEO in DiaGenic,
MD PhD Henrik Lund.
Contact:

Henrik Lund, CEO

Telephone: 47 90971219

e-mail:  
About DiaGenic ASA

DiaGenic...